Stockscreener 앱 받기
1.565
1.26%
-0.02
시간 외 거래:
1.57
0.005
+0.32%
전일 마감가:
$1.585
열려 있는:
$1.56
하루 거래량:
27,002
Relative Volume:
0.08
시가총액:
$11.75M
수익:
$149.50K
순이익/손실:
$-6.96M
주가수익비율:
-1.1507
EPS:
-1.36
순현금흐름:
$-6.37M
1주 성능:
-8.70%
1개월 성능:
-10.57%
6개월 성능:
+11.79%
1년 성능:
+21.32%
1일 변동 폭
$1.54
$1.57
1주일 범위
$1.54
$1.77
52주 변동 폭
$1.03
$2.55
Biorestorative Therapies Inc Stock (BRTX) Company Profile
명칭
Biorestorative Therapies Inc
전화
(631) 760-8100
주소
40 MARCUS DRIVE, MELVILLE
BRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BRTX
Biorestorative Therapies Inc
|
1.565 | 12.86M | 149.50K | -6.96M | -6.37M | -1.36 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Biorestorative Therapies Inc 주식(BRTX)의 최신 뉴스
What is Roth Capital’s Estimate for BRTX Q2 Earnings? - Defense World
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q1 2025 Earnings Call Transcript - Insider Monkey
BioRestorative Therapies’ Earnings Call: Progress Amid Challenges - TipRanks
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates - MSN
BioRestorative Therapies Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: BioRestorative Therapies Q1 2025 sees widened losses - Investing.com Nigeria
BioRestorative Therapies Reports Q1 2025 Results and Updates - TipRanks
BIORESTORATIVE THERAPIES Earnings Results: $BRTX Reports Quarterly Earnings - Nasdaq
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update - Ortho Spine News
BioRestorative's Spine Treatment Gets FDA Fast Track After Positive 52-Week Trial Data - Stock Titan
BioRestorative Therapies (BRTX) Reports Positive Initial Results in Phase 2 Trial | BRTX Stock News - GuruFocus
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data - Ortho Spine News
BioRestorative Therapies, Inc. Announces Positive Preliminary Data from Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease at ISCT 2025 Annual Meeting - Nasdaq
BioRestorative Therapies (BRTX) to Release Quarterly Earnings on Wednesday - Defense World
BioRestorative Therapies Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025 - The Manila Times
BioRestorative Therapies, Inc. to Release First Quarter 2025 Financial Results on May 14, 2025 - Nasdaq
BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025 - Stock Titan
BioRestorative To Present A BRTX-100 Clinical Update At ISCT 2025 - Barchart.com
Reviewing BioRestorative Therapies (OTCMKTS:BRTX) and Silence Therapeutics (OTCMKTS:SLNCF) - Defense World
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading Down 2.3% – Here’s Why - Defense World
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies - The Globe and Mail
EQS-News: Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies - markets.businessinsider.com
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease - FinancialContent
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities - TradingView
BioRestorative CEO Reveals Latest Clinical Breakthroughs and Market Expansion Plans - Stock Titan
BioRestorative unaffected by new U.S. tariffs, continues clinical trials - Investing.com South Africa
BioRestorative confirms no material impact from reciprocal tariffs - marketscreener.com
BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States - Yahoo
FDA Fast-Tracks BioRestorative's Therapy as $10M Cash Shields Growth - Stock Titan
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Up 3.9% – Time to Buy? - Defense World
BioRestorative Therapies Reports Strong Growth Amid Challenges - MSN
Equities Analysts Issue Forecasts for BRTX FY2029 Earnings - Defense World
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q4 2024 Earnings Call Transcript - MSN
Earnings call transcript: BioRestorative’s Q4 2024 sees revenue growth, stock dip - Investing.com India
BioRestorative Therapies (BRTX) Projected to Post Earnings on Friday - Defense World
BioRestorative Therapies Reports Financial Gains and Clinical Progress - TipRanks
BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update - TradingView
175% Revenue Surge: BioRestorative's Breakthrough Year With FDA Fast Track Success - Stock Titan
Earnings Preview For BioRestorative Therapies - Benzinga
BIORESTORATIVE THERAPIES Earnings Preview: Recent $BRTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
BioRestorative Therapies Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
BioRestorative Therapies (BRTX) Projected to Post Earnings on Thursday - Defense World
Biorestorative Therapies Inc (BRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.33%
1.09%
자본화:
|
볼륨(24시간):